MRK Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 32.71% compared to Merck &'s net margin of 19.72%. Merck &'s return on equity of 39.02% beat Gilead Sciences's return on equity of 32.29%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 32.87%. On the other hand Gilead Sciences has an analysts' consensus of $115.02 which suggests that it could grow by 17.51%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4%. Gilead Sciences offers a yield of 3.17% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Merck & quarterly revenues are $15.5B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Merck &'s net income of $5.1B is higher than Gilead Sciences's net income of $1.3B. Notably, Merck &'s price-to-earnings ratio is 11.51x while Gilead Sciences's PE ratio is 20.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.14x versus 4.29x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 32.71% compared to Merck &'s net margin of 50.24%. Merck &'s return on equity of 39.02% beat Johnson & Johnson's return on equity of 30.18%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 32.87%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.18%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Merck & pays 45.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Merck &'s net income of $5.1B is lower than Johnson & Johnson's net income of $11B. Notably, Merck &'s price-to-earnings ratio is 11.51x while Johnson & Johnson's PE ratio is 17.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.14x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 32.71% compared to Merck &'s net margin of -907.48%. Merck &'s return on equity of 39.02% beat Moderna's return on equity of -29.23%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 32.87%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.23%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Moderna quarterly revenues of $107M. Merck &'s net income of $5.1B is higher than Moderna's net income of -$971M. Notably, Merck &'s price-to-earnings ratio is 11.51x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.14x versus 3.03x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 32.71% compared to Merck &'s net margin of 26.7%. Merck &'s return on equity of 39.02% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 32.87%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 43.26%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Merck & pays 45.8% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Merck &'s net income of $5.1B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Merck &'s price-to-earnings ratio is 11.51x while Regeneron Pharmaceuticals's PE ratio is 14.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.14x versus 4.52x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.